{"id":"pirarubicin-and-cyclophosphamide","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Cardiotoxicity"},{"rate":null,"effect":"Hemorrhagic cystitis"}]},"_chembl":{"chemblId":"CHEMBL2354444","moleculeType":"Small molecule","molecularWeight":"627.64"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pirarubicin, a derivative of daunorubicin, intercalates between DNA base pairs and inhibits topoisomerase II, preventing DNA unwinding and causing double-strand breaks in rapidly dividing cells. Cyclophosphamide is a nitrogen mustard alkylating agent that forms covalent cross-links in DNA, preventing replication and transcription. This combination targets cancer cells through complementary mechanisms of DNA damage.","oneSentence":"Pirarubicin is an anthracycline that intercalates into DNA and inhibits topoisomerase II, while cyclophosphamide is an alkylating agent that cross-links DNA, together inducing cancer cell death.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:00:28.950Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breast cancer (as part of chemotherapy regimen)"},{"name":"Various solid tumors and hematologic malignancies"}]},"trialDetails":[{"nctId":"NCT07410234","phase":"PHASE2","title":"Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-02-21","conditions":"Breast Cancer","enrollment":110},{"nctId":"NCT07378306","phase":"PHASE2","title":"FMD and Neoadjuvant Chemo-immunotherapy in TNBC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-01","conditions":"Breast Cancer","enrollment":80},{"nctId":"NCT07178171","phase":"PHASE1","title":"A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2025-11-06","conditions":"TNBC, Triple Negative Breast Cancer","enrollment":30},{"nctId":"NCT06933394","phase":"PHASE2","title":"Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-05-01","conditions":"Neuroblastoma","enrollment":92},{"nctId":"NCT02396043","phase":"PHASE2","title":"Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-03","conditions":"Lymphoma, Lymphoblastic","enrollment":50},{"nctId":"NCT05527912","phase":"PHASE2","title":"A Phase II Study of Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2023-02-24","conditions":"Double Express Diffuse Large B-cell Lymphoma","enrollment":45},{"nctId":"NCT05558722","phase":"PHASE2","title":"Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast Cancer","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2022-11-30","conditions":"Breast Cancer Stage II","enrollment":30},{"nctId":"NCT05287308","phase":"NA","title":"Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study","status":"NOT_YET_RECRUITING","sponsor":"Chinese Academy of Medical Sciences","startDate":"2022-03","conditions":"Breast Cancer","enrollment":500},{"nctId":"NCT04437160","phase":"PHASE2","title":"Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy","status":"RECRUITING","sponsor":"Chinese Academy of Medical Sciences","startDate":"2020-02-01","conditions":"Triple Negative Breast Cancer","enrollment":286},{"nctId":"NCT04126811","phase":"PHASE2","title":"Apatinib Combined With Chemotherapy in the Treatment of Soft Tissue Sarcoma","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2019-06-01","conditions":"Soft Tissue Sarcoma","enrollment":120},{"nctId":"NCT03925233","phase":"","title":"Breast Cancer Treatment Based on Organ-like Culture","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2019-01-02","conditions":"Breast Cancer Organoids","enrollment":300},{"nctId":"NCT03892330","phase":"PHASE4","title":"Combination Therapy of Anthracyclines for Children With Nephroblastoma","status":"NOT_YET_RECRUITING","sponsor":"Shengjing Hospital","startDate":"2019-06-01","conditions":"0.5-14 Year Old Children With Nephroblastoma","enrollment":120},{"nctId":"NCT02953184","phase":"PHASE2","title":"Marched Pair Study Conventional Doxorubicin(DOX) Versus Pegylated Liposomal Doxorubicin(PLD) Neoadjuvant Chemotherapy","status":"UNKNOWN","sponsor":"Jilin University","startDate":"2016-11","conditions":"Antineoplastic Combined Chemotherapy Protocols","enrollment":160},{"nctId":"NCT01746992","phase":"PHASE4","title":"CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2012-09","conditions":"ALK-negative Anaplastic Large Cell Lymphoma, Peripherial T Cell Lymphoma,Not Otherwise Specified, Angioimmunoblastic T Cell Lymphoma","enrollment":200},{"nctId":"NCT02903524","phase":"PHASE4","title":"Doxorubicin Hydrochloride Liposome Injection Combination With Cyclophosphamide vs Pirarubicin Combination With Cyclophosphamide in Patients With Locally Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2016-09","conditions":"Breast Cancer","enrollment":300},{"nctId":"NCT02613026","phase":"PHASE3","title":"Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer","status":"COMPLETED","sponsor":"307 Hospital of PLA","startDate":"2009-07","conditions":"Breast Neoplasms","enrollment":104},{"nctId":"NCT01430013","phase":"PHASE2","title":"Trial of Endostar Combined With CHOPT for T Cell Lymphoma","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2011-06","conditions":"T Cell Lymphoma","enrollment":30},{"nctId":"NCT00131053","phase":"PHASE2","title":"Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL)","status":"UNKNOWN","sponsor":"Japan Adult Leukemia Study Group","startDate":"2002-09","conditions":"Lymphoblastic Leukemia, Acute","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":30,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"pirarubicin and cyclophosphamide","genericName":"pirarubicin and cyclophosphamide","companyName":"Hebei Medical University Fourth Hospital","companyId":"hebei-medical-university-fourth-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pirarubicin is an anthracycline that intercalates into DNA and inhibits topoisomerase II, while cyclophosphamide is an alkylating agent that cross-links DNA, together inducing cancer cell death. Used for Breast cancer (as part of chemotherapy regimen), Various solid tumors and hematologic malignancies.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}